冠心病患者的慢性肾病筛查:跨国INTERASPIRE研究
该研究纳入14个国家4548例冠心病患者,在诊断后6至24个月评估eGFR和UACR,发现32%存在慢性肾病,其中51.3%仅凭eGFR会被漏诊;中位随访1年主要复合终点发生率为7.9%,肾脏风险高风险组最高,而心肾保护治疗使用率低。
要点
- 冠心病患者中慢性肾病患病率达32%,仅用eGFR会漏诊51.3%。
- 肾脏风险高风险组主要心血管事件发生率最高(男13.0%,女11.8%)。
- 心肾保护治疗仅少数患者充分使用,存在较大改善空间。
核心结论
- 冠心病患者应早期筛查慢性肾病,最好同时检测eGFR和UACR以完整诊断。
- 若不检测UACR,约一半慢性肾病患者将被漏诊。
- 心肾保护治疗使用率低,改善潜力大。
研究设计与样本
- 跨国观察性研究,纳入14个国家4548例冠心病患者(79.6%为男性,年龄18-80岁)。
- 在冠心病诊断后6至24个月评估eGFR和UACR。
- 3865例有完整肾功能和心肾保护治疗信息,3577例(92.5%)有中位1年随访数据。
主要发现
- 按KDIGO分类,32%存在慢性肾病,其中19.7%为低中风险,6.9%为高风险,5.6%为极高风险。
- 不检测UACR时,51.3%的慢性肾病患者会被漏诊。
- 主要终点(心血管死亡、心肌梗死、卒中、心衰住院首次发生)发生率为7.9%,KDIGO高风险组最高(男13.0%,女11.8%)。
- 该关系独立于其他危险因素,且在指数检查后不久即显现。
- 仅少数患者接受了充分的心肾保护治疗。
临床怎么用
- 对冠心病患者应同时检测eGFR和UACR以筛查慢性肾病。
- 根据KDIGO风险分层识别高风险患者,加强心肾保护治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease (CKD) is an important risk factor for the progression of coronary artery disease (CAD). OBJECTIVES: The purposes of this study were to quantify the prevalence of CKD in CAD patients from 14 countries from all World Health Organization regions and to evaluate the prognostic value of estimated glomerular filtration rate (eGFR) and urinary albumin/creatinine ratio (UACR). METHODS: A total of 4,548 patients with CAD were included (79.6% were males; age range: 18-80 years). They were assessed for eGFR and UACR 6 to 24 months after the CAD diagnosis. Complete information on kidney function and cardio-renal protective therapy was available for 3,865 patients and follow-up data after a median of 1 year were available for 3,577 (92.5%). RESULTS: CKD according to the Kidney Disease Improving Global Outcomes classification was present in 32% of whom 19.7% were classified as low-moderate, 6.9% as high, and 5.6% as very high risk. Without UACR, 51.3% of them would have been undetected. The primary event, first of cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure, was observed in 7.9%, with the highest incidence in the Kidney Disease Improving Global Outcomes high-risk group (men: 13.0%; women: 11.8%). This relationship was independent of other risk factors and evident soon after the index examination. Only a minority of the patients received adequate cardio-renal protective therapy. CONCLUSIONS: Early screening for CKD in patients with CAD is important and should preferably include both eGFR and UACR to provide a complete diagnosis. Without UACR, half of those with CKD would remain undetected. Treatment with cardio-renal protective therapy was low, providing great potential for improvement.
引用
- Al-Azzawy SM, De Bacquer D, McEvoy JW, et al. Chronic Kidney Disease Screening in Patients With Coronary Heart Disease: The Multinational INTERASPIRE Study. J Am Coll Cardiol. 2026. PMID: 41920136. doi:10.1016/j.jacc.2026.01.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。